Exploiting the kinetic interplay between GPIb -VWF binding interfaces to regulate hemostasis and thrombosis by Chen, Jianchung et al.
 1 
Exploiting the kinetic interplay between the GPIbα–VWF binding interfaces 
to regulate hemostasis and thrombosis 
 
Jianchung Chen,1 Hairu Zhou,1 Alexander Diacovo,1 X. Long Zheng,3 Jonas Emsley,4 
and Thomas G. Diacovo1,2 
1Department of Pediatrics, Columbia University Medical Center, New York, New York, 
10032, USA. 2Department of Pathology and Cell Biology, Columbia University Medical 
Center, New York, New York, 10032, USA. 3Department of Pathology and Laboratory 
Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104 
USA. 4Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, 
University Park, Nottingham, NG72RD, UK.  
Correspondence 
 
Thomas Diacovo, MD 
Columbia University  
1130 St. Nicholas Ave, Room 924 
New York, NY 10032 
Tel: 212-851-4683 
E-mail: td2142@cumc.columbia.edu 
 
 
Short title: Regulating adhesion between platelets and VWF 
 
Text word count: 4,341 
Text abstract count: 200 
Number of figures: 6, and 2 supplemental figures 
Number of tables: 1 
Number of references: 43 
  
 2 
Key points  
 
 
• GPIbα–VWF-A1 bond lifetime governs platelet–VWF interactions and can be 
altered to correct defects in hemostasis or prevent thrombosis. 
 
• Targeting a distinct binding interface between GPIbα and VWF-A1 offers a 
unique therapeutic approach to reducing platelet-driven thrombosis 
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Abstract 
Platelet–VWF interactions are tightly controlled to prevent vascular occlusion due to 
premature aggregate formation. Although multiple mechanisms may regulate this 
process, it is unclear whether the inherent properties of the bond formed the platelet 
receptor GPIbα and the A1 domain of VWF can influence the site and extent to which 
platelets bind VWF. Here, we demonstrate that the kinetic interplay between two distinct 
regions of contact between this receptor–ligand pair not only permit maximal platelet 
accrual at sites of arterial injury, but can be manipulated to correct defective hemostasis 
or prevent thrombosis. This was accomplished by generating VWF-A1 knock-in mice 
with mutations that enhance (I1309V) or disrupt (R1326H) GPIbα binding and by 
targeting the complex with an allosteric inhibitor. Incorporation of R1326H mutation in 
the major site shortened bond lifetime, yielding defects in hemostasis and thrombosis 
comparable to VWF deficient animals. Similarly, pharmacologic disruption of the major 
interface prevented arterial thrombosis. However, combining the R1326H mutation with 
the I1309V mutation located near the minor site normalized bond kinetics and restored 
the hemostatic and thrombotic properties of VWF. Hence, an important biophysical-–
biological relationship is revealed and the therapeutic benefits of modifying the GPIbα–
VWF-A1 binding interfaces established. 
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Introduction  
 
 
The ability of blood borne cells to perform their designated biological function(s) 
requires cell surface adhesion molecules to engage counter-receptors at the appropriate 
time and location. For example, platelets and von Willebrand factor (VWF) co-exist in 
circulating blood and must interact at sites of arterial injury in order to promote effective 
hemostasis. This process is triggered upon the binding of plasma VWF to exposed 
components of the injured vessel wall where it can then initiate the attachment of 
platelets under shear flow conditions.1,2 VWF is a multimeric plasma glycoprotein 
composed of functionally distinct types of domains that are either duplicated or 
triplicated in the following order from the N-terminus: D'-D3-A1-A2-A3-D4-B1-B2-B3-
C1-C2-CK.3,4 It is the interaction between VWF-A1 domain and the platelet receptor 
glycoprotein Ib alpha (GPIbα) that initiates primary hemostasis by bringing platelets into 
close proximity with reactive substrates generated at the site of arterial damage.5-8 The 
clinical significance of this interaction is underscored by the increased bleeding 
tendencies of individuals who either lack the plasma protein or possess mutations within 
the A1 domain of VWF. In the latter case, this includes mutations that limit binding (type 
2M) or paradoxically enhance interactions (type 2B), both of which are associated with 
the hereditary bleeding disorder known as von Willebrand disease (VWD).3,4 
 Against this background, structure analyses of native and mutant complexes have 
provided insights into the nature of the interactions that support adhesion between this 
receptor–ligand pair and possible mechanisms by which mutations alter this process. The 
structure reveals a major and minor binding site for GPIbα on the surface of the A1 
domain that is bridged by an area of solvated charge interaction.9,10 Type 2M mutations, 
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located in or directly adjacent to the larger contact surface, may disrupt electrostatic 
interactions between this receptor–ligand pair or induce structural changes that reduce 
GPIbα binding. In contrast, type 2B mutations are clustered in close proximity to the 
minor site near the termini of the domain and may alter the conformation of a region 
known as the α1-β2 loop.9-12 Consequently, this is thought to provide an essential 
energetic contribution that augments binding affinity9 or reduce a steric clash that would 
impede adhesion.13 Clinically, this enhanced binding is believed to result in bleeding by 
permitting VWF multimers with the greatest hemostatic potential to aggregate 
spontaneously with platelets in blood and ultimately be cleared from the circulation.3,4 
Although such studies provide insight into mechanism(s) by which mutations associated 
with VWD may alter binding between platelets and VWF, they cannot account for 
interactions involving sites outside of the A1 and GPIbα binding domains or external 
influences such as shear flow that play a role in regulating hemostasis and thrombosis.14 
Indeed, several mechanisms have been identified that may prevent VWF–platelet 
aggregate formation in the circulation. This includes shielding of VWF-A1 by the 
adjacent D'D3 domains,15 the inhibitory effects of the β2-glycoprotein I,16 and the ability 
of shear flow to activate the VWF-A1 so that it can then engage GPIbα.17 Moreover, it 
has been demonstrated that forces generated by flowing blood can promote the unfolding 
and elongation of VWF so that it exposes multiple A1 domains.18  
 An additional mechanism that has not been fully explored is the contribution that 
the physicochemical properties of the bond formed between VWF-A1 and GPIbα play in 
regulating platelet–VWF interactions at sites of vascular injury. Indeed, detailed analyses 
of the kinetic and mechanical properties of this receptor–ligand pair have yielded insight 
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into the biophysical consequences of the predicted allosteric change associated with type 
2B mutations.19-22 That said, it remains unclear whether specific properties of the GPIbα–
VWF-A1 bond predicted to regulate platelet–VWF interactions correspond with 
biological reality.23-25 
 
 In the current study, we address this shortcoming by performing a detailed kinetic 
analysis of WT and mutant murine GPIbα–VWF-A1 complexes and then validating these 
observations using transgenic mice harboring modified VWF-A1 domains. We also probe 
the binding interface using a novel allosteric inhibitor that prevents the formation of key 
interactions between this receptor–ligand pair. Our data reveal that the physicochemical 
properties of the distinct regions of contact between this receptor–ligand pair contribute 
to a composite biophysical signature required for effective hemostasis and arterial 
thrombus formation. 
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Methods  
Modeling of murine GPIbα–VWF-A1 complexes  
Crystal structures of the human GPIbα–VWF-A1 complex have been described for WT 
and for the complex formed between the GOF mutations R1306Q and I1309V in VWF-
A1 and the platelet type GOF mutation M239V in GPIbα.9,10,13,26 The human platelet 
receptor was used as a template for mouse GPIbα. Consensus rotamers with minimal 
steric clashes were chosen, followed by adjustments to create reasonable van der Waals 
interactions and H-bonding using COOT (http://www.biop.ox.ac.uk/coot/).  
 A consensus model of the human receptor–ligand pair was used to build its 
murine counterpart. This included the double mutant VWF-A1 (I1309V, R1326H) 
complex that was based on the human VWF-A1 (R1306Q) mutant complex using the 
program SWISSMODEL (http://swissmodel.expasy.org/).10 Figures were created using 
PYMOL. 
Mice 
The generation of the VWFR1326H mutant mouse has been previously described.27 A 
similar targeting strategy was used to introduce the double mutation I1309V, R1326H 
into exon 28 of the murine VWF gene or to substitute in the human A1 domain. VWF 
deficient mice were purchased from The Jackson Laboratory. All animals were on a 
C57BL/6J background and kept in a pathogen-free facility. Experiments were performed 
in accordance to the guidelines set forth by Institutional Animal Care and Use Committee 
at Columbia University Medical Center.  
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Analysis of VWF expression and function  
Detection and/or measurement of murine VWF A1-A2-A3 domain transcripts, plasma 
VWF antigen levels, functional factor VIII levels, and multimer pattern were performed 
as previously described.27-30  
 
 Platelet adhesion in flow 
A parallel-plate flow chamber was used to assess platelet attachment and translocation on 
surface-immobilized plasma VWF or recombinant VWF-A1 protein.27 Generation and 
purification of recombinant proteins were performed as previously described.20,26 Citrated 
whole blood (150 µl) collected via cardiac puncture from anesthetized WT and mutant 
VWF mice or from healthy human volunteers (venipuncture) was perfused over the 
immobilized substrates at wall shear rates ranging from 100 s-1 to 1,600 s-1 for 2 min, 
followed by washing with Tyrode's buffer. The number of platelets attached per unit area 
and translocation velocities were determined by off-line analysis. For inhibition studies, 
OS1 peptide was generated and purified as previously described.31 The inhibitor was 
added to 1 ml of citrated whole blood 5 minutes prior to perfusing over surface-
immobilized substrates.  
 
Platelet aggregation 
The ability of ristocetin (Chronolog Corporation) to aggregate human platelets in plasma 
obtained from healthy volunteers or VWF mutant mice was assessed using a Lumi-
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Aggregometer (model 540 VS, Chronolog Corporation).32 In brief, citrated whole blood 
obtained by cardiac puncture from anesthetized mice or collected via venipuncture from 
healthy volunteers was centrifuged to obtain platelet poor plasma (PPP). Subsequently, 
lyophilized human platelets (Bio/Data Corporation) reconstituted in TBS were added to 
plasma at a 4:1 ratio (v/v) and a baseline obtained for 2 minutes prior to adding ristocetin 
(1.25 mg/ml). Aggregation (1,200 rpm, 37°C) was allowed to proceed for 6 min. Results 
are reported as maximum percent change in light transmittance from baseline with TBS 
used as a reference. For inhibition studies, platelet / PPP mixture was incubated with OS1 
peptide (0.1 µg/ml to 5 µg/ml) for 5 min prior to the addition of ristocetin.  
 
 In vivo thrombus formation.  
Administration of anesthesia, insertion of vascular catheters, fluorescent labeling of 
platelets, and surgical preparation of the cremaster muscle have been previously 
described.27,32 A pulsed nitrogen dye laser was used to induce arteriole injury in the 
cremaster muscle of anesthetized 8-12 week old animals. Mouse or human platelet-vessel 
wall interactions were visualized by fluorescen ce microscopy. Human platelets were 
administered by continuous infusion (700,000/µl at 25 µl/min) through a catheter placed 
in the ipsilateral femoral artery 2 minutes before and during laser-induced injury. For 
inhibition studies, 20 µg of OS1 peptide in 100 µl of saline was administered i.v. 5 min 
prior to the administration of human platelets. The extent of thrombus formation was 
assessed for 2 min post injury and the area (µm2) of coverage. 
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Tail bleeding assay 
Bleeding times were measured in 8-week old mice after amputating 1 cm of the tail tip 
and then placing the tail in a physiological saline solution (37°C) as previously 
described.27 
 
Microsphere tethering frequency 
The rate of complex formation was evaluated by measuring the frequency of tethering 
events between surface-immobilized mouse platelets and microspheres coated with a low 
site density of recombinant WT or mutant VWF-A1.20,21 This was determined by 
observing the number of beads that paused, but did not translocate, at wall shear rates 
ranging from 10 s-1 to 300 s-1. This value was then normalized by dividing the number of 
beads that formed transient tethers by the number of non-interacting beads transported 
across the field of view in the focal plane of the immobilized platelet substrate. 
Estimation of the amount of VWF-A1 coupled to beads was determined using a 
calibrated microbead system (Flow Cytometry Standards) following manufacturer’s 
instructions. The site density of VWF-A1 on beads was estimated to be ~35 sites/µm2. 
 
Dissociation rate constants of transient tethers  
The duration of transient tethers was estimated for VWF-A1-coated microspheres 
interacting with surface-immobilized platelets at wall shear stresses ranging from 0. 5 to 
3.0 dyn/cm2. 20,21  Only one tethering event per bead was counted during the observation 
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period. The duration of these interactions was measured by recording images at a frame 
rate of 235 frames per second using 60X DIC objective (oil immersion). A total of 30–50 
interact pause times for each wall shear stress was recorded. Dissociation rate constants 
were determined by plotting the natural log of the number of VWF-A1–coated 
microspheres that interacted as a function of time after the initiation of tethering. The 
slope of the line = -koff. The force acting on the tether bond was calculated from force 
balance equations (bead radius of 3.5μm) satisfied with a tether angle θ of 57.2 
degrees.20,21 
 
Statistical analyses  
Details for the calculation of maximum likelihood estimates (MLEs) for the off-rates 
(koff) and Bell model parameters (k0off, σ) can be found in supplemental Methods. 
Statistical analysis of all other data was determined using unpaired Student’s t-test 
(GraphPad Prism software). Values were considered significant at P < 0.05.  
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Results  
Structural and functional changes associated with I1309V and R1326H mutations 
 To determine the interplay between known contact surfaces and to establish the 
role that the biophysical properties of the GPIbα–VWF-A1 bond play in regulating 
platelet–VWF interactions, we chose mutations within the major or minor contact 
interfaces of the murine A1 domain that enhance (I1309V) or disrupt (R1326H) binding. 
The I1309V mutation is known to cause type 2B VWD,33 while the R1326H substitution 
impairs interactions with mouse GPIbα.27 Interestingly, several mammalian species 
including humans have a histidine in lieu of arginine at position 1326 within the A1 
domain.34 Thus, murine VWF is ideal for determining how this particular amino acid 
substitution alters the biophysical properties of the GPIbα–VWF-A1 bond and its ability 
to support hemostasis and thrombosis. Models of WT and mutant murine complexes were 
built to better understand the effect of the mutations on binding (Figure 1A). Although 
crystal structure analyses have yet to identify the exact mechanism by which the I1309V 
mutation augments adhesion,9,13 it is located in the α1-β2 loop adjacent to the type 2B 
mutation R1306Q.9,10 The latter mutation is believed to result in a local conformational 
change with a re-positioning of residues Q1311 and R1334 that reinforce interactions 
with human GPIbα.9 Figure 1B illustrates the position of residue 1309 in the context of 
the complex formed with murine GPIbα and the augmentation in binding that occurs 
upon re-positioning of residues Q1311 and R1334.  
 To understand how these mutations affect adhesion under flow conditions, we 
generated recombinant murine VWF-A1 (rVWF-A1) proteins containing the R1326H 
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and I1309V substitutions and determined their ability to support mouse platelet 
interactions when surface-immobilized in a parallel plate flow system.27 The R1326H 
mutation impaired mouse platelet accumulation and increased translocation velocity ~13-
fold as compared to WT rVWF-A1 (Figure 1C-D). In contrast, the I1309V mutation 
decreased translocation velocity ~5-fold and greatly augmented platelet accumulation. 
Strikingly, rVWF–A1 containing both amino acid substitutions yielded an adhesive 
phenotype comparable to WT.  
 
I1309V and R1326H mutations differentially alter bond formation and dissociation  
  To determine whether the biophysical properties of rVWF-A1 expressing both 
mutations truly reflect that of the WT complex, we analyzed the formation and 
dissociation of transient adhesive events, known as tether bonds, that occur when flowing 
rVWF-A1–coated microspheres transiently interact with GPIbα expressed on surface-
immobilized mouse platelets.20,21 On-rate was determined by evaluating the frequency 
with which microspheres interacted with surface-immobilized mouse platelets at various 
wall shear rates. Whereas the I1309V mutation enhanced the rate of association ~3.5–fold, 
this was abolished when combined with the R1326H substitution (Figure 2A). In fact, 
murine rVWF-A1 possessing the double mutation displayed a rate of association that 
more closely resembled the WT complex with a maximal tethering frequency at a wall 
shear rate of 85 s-1. 
 The effects of the mutations on the kinetics of dissociation (koff) were determined 
measuring the lifetime of tether bonds and their response to an applied force.20,21 We 
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previously showed the utility of this system for assessing the biophysical properties of the 
interaction between human GPIbα and rVWF-A1. Moreover, the use of microspheres 
with a uniform size and shape permits the calculation of the amount of shear force acting 
on the tether bond. As previously observed for the human complex, the distribution of 
interaction times indicated that the majority of WT and mutant tether bonds fit a straight 
line, the regressed slope of which corresponded to -koff (Figure 2B-E). In addition, the rate 
of dissociation behaved in accordance with the equation of Bell, which states that koff = 
k0off exp(σFb/kT), where Fb is the applied force, k0off  is the dissociation rate constant in 
the absence of force, kT is the thermal energy, and σ (reactive compliance) relates the 
sensitivity of bond off-rate to an applied force.35 The larger the values for k0off and σ, the 
shorter the bond lifetime (1/ k0off) and the more prone the receptor–ligand interaction is to 
force-driven dissociation, respectively. Maximum likelihood estimates (MLE) of the 
kinetics of GPIbα–VWF-A1 interactions and their subsequent fit to the Bell equation 
were performed.36 Regression analyses of these simulations fit the data at bond forces 
ranging from 36 pN to 217 pN and thus permitted the determination of k0off and σ (Figure 
2F and Table 1). Whereas the major effect of the I1309V substitution was to prolong the 
lifetime of the tether bond (6-fold), R1326H shortened its duration (2.5-fold). However, 
the kinetic (k0off) and mechanical (σ) properties of rVWF-A1 bearing both mutations were 
nearly identical to that of the native complex. 
 
Hemostatic and thrombotic properties of murine VWF possessing mutant A1 
domains 
 15
To determine whether the predictions based on biophysical studies truly have biological 
relevance, we generated knock-in mice that express either the R1326H (VWF R1326H) 
mutation alone27 or in combination with I1309V (VWF I1309V, R1326H) (supplemental 
Figure 1A-C). VWF gene transcription, multimer pattern, antigen levels as well as factor 
VIII function and platelet counts were similar to WT littermates (supplemental Figure 
1D-H). Consistent with the reduction in bond lifetime and impaired adhesion, animals 
expressing the R1326H mutation had prolonged tail bleeding times and a diminished 
capacity to form arterial thrombi (Figure 3A-B). In fact, VWF R1326H mice possessed a 
phenotype similar to that observed for mice lacking this plasma protein (VWF KO). 
Remarkably, the additional incorporation of the I1309V mutation corrected the observed 
perturbations in platelet–VWF interactions. Not only did VWF-A1 double mutant 
animals have hemostatic properties similar to WT littermates, but also laser-induced 
thrombi were comparable in size to mice possessing the WT plasma protein (Figure 3A-
B). Direct evidence that plasma VWF I1309V, R1326H has adhesive properties equivalent to 
its WT counterpart is demonstrated by its ability to support mouse platelet accumulation 
and translocation velocities at similar levels (Figure 3C-D). This was not the case for 
plasma VWF R1326H which impaired platelet adhesion and yielded a ~3-fold increase in 
translocation velocity. These data support a close association between the lifetime of the 
GPIbα–VWF-A1 bond and the ability of these hemostatic elements to support critical 
biological processes.  
 
Targeting the major binding interface between human GPIbα and VWF-A1  
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Given the importance of the major contact site in supporting mouse platelet–VWF 
interactions in vivo, we next explored the therapeutic utility of targeting this region in the 
human complex. This was accomplished by using a novel cyclic peptide, termed OS1, 
which was isolated from a cysteine-constrained phage display library.31 It interacts with 
the curved concave face of the GPIbα leucine-rich repeat,37 stabilizing a conformation of 
a regulatory loop known as the β-switch10 so that it prevents the formation of electrostatic 
interactions essential for binding to the VWF-A1 domain (Figure 4A). However, the 
effect of OS1 is limited to human GPIbα as demonstrated by its inability to reduce mouse 
platelet–VWF interactions in vitro and in vivo (Figure 4B-C). In contrast, incubation of 
whole blood from healthy volunteers with the inhibitor not only limited platelet 
accumulation on surface-immobilized human rVWF-A1 protein, but also impaired 
ristocetin-induced platelet aggregation in a dose dependent manner (Figure 4D-E).  
 
 To directly test the ability of OS1 to prevent human platelet-mediated arterial 
thrombosis, we generated an animal in which the majority of the murine A1 domain was 
replaced with its human counterpart (supplemental Figure 2A-B). VWF gene 
transcription, multimer pattern, antigen levels and platelet counts in VWF HA1 mice were 
similar to WT littermate controls (supplemental Figure 2C-F). In addition, animals 
containing the human VWF-A1 domain manifested impaired platelet–vessel wall 
interactions that resulted in a prolongation in tail bleeding time as well as a reduction in 
thrombus size in laser-injured arterioles (Figure 5A-B). Consistent with these 
observations was the inability of surface-immobilized plasma VWF HA1 to support mouse 
platelet accumulation in flow (Figure 5C). In the presence of human platelets, however, 
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VWF HA1 mice formed large and often occlusive thrombi in laser-injured arterioles of 
nearly identical size to that observed in their VWF R1326H counterparts (Figure 5D). 
Accumulation of human platelets on surface-immobilized plasma VWF from either 
animal was also comparable (Figure 5E). Yet, only plasma VWF from mice possessing 
the human VWF-A1 domain supported ristocetin-induced platelet agglutination / 
aggregation of human platelets demonstrating that the R1326H mutation in murine VWF-
A1 was not sufficient to support this process (Figure 5F). Importantly, the OS1 peptide 
was able to impair human platelet accumulation on surface-immobilized plasma VWF 
HA1
 and inhibited ristocetin-induced platelet agglutination / aggregation (Figure 6A-B). 
Moreover, human platelet-mediated thrombus formation in arterioles of VWF HA1 mice 
was reduced by >80% in the presence of the inhibitor (Figure 6C). The data demonstrate 
the potential therapeutic utility in targeting the major contact interface formed between 
the human GPIbα–VWF-A1 complex. 
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Discussion  
Detailed structural and biophysical analyses of small regions of contact between GPIbα 
and VWF-A1 have yielded tremendous insight into the relationship between force-
lifetime-and-chemistry of an interaction critical for supporting hemostasis and thrombosis. 
Here, we have taken a unique approach to better understand the role that the kinetic 
properties of the contact surfaces formed between this receptor–ligand pair play in 
supporting these biologically relevant processes. By generating animals with mutations 
contained within the major and minor binding sites of murine VWF-A1 that either reduce 
or enhance attachment to GPIbα, we provide the first in vivo evidence that bond lifetime 
does play an important role in regulating platelet–VWF interactions at sites of arterial 
injury. 
 To determine whether data obtained using a murine-based system were applicable 
to the human receptor–ligand pair, we first measured the kinetic properties of the murine 
GPIbα–VWF-A1 bond and its response to an applied force. Values for the intrinsic off-
rate were similar between the species (k0off values of 3.05 ± 0.55 s-1 and 3.45 ± 0.37 s-1 for 
the mouse and human complex, respectively). However, the reactive compliance (σ) for 
the WT murine complex was ~1.5-fold higher than for its human counterpart (0.028 ± 
0.001 nm versus 0.018 ± 0.002 nm, respectively), suggesting that the interaction between 
the murine receptor–ligand pair may be slightly more prone to dissociate upon the 
application of hydrodynamic force. The effects of the I1309V substitution mirrored that 
of the human rVWF-A1 mutant20, including the reduced requirement for shear flow to 
promote GPIbα interactions with VWF-A1 and a prolongation in bond lifetime. 
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Surprisingly, the observed alterations in adhesion did not persist when this mutation was 
combined with R1326H. In fact, the biophysical properties of the double mutant bond 
more closely resembled that of the native complex. These observations led us to predict 
that murine plasma VWF I1309V, R1326H should possess hemostatic and thrombotic 
properties similar to the native plasma protein if bond lifetime plays an important role in 
these processes. This was borne out by the fact that I1309V, R1326H double knock-in 
mice had tail bleeding times and formed arterial thrombi of similar size to that observed 
for WT littermates. Based on these observations we conclude that the major and minor 
contact interfaces not only contribute to a biophysical signature well suited for supporting 
platelet–VWF interactions under the hydrodynamic conditions encountered in the arterial 
circulation, but also that they must be maintained within strict limits in order to optimize 
platelet accumulation at sites of vascular injury.  
 Although the precise mechanism(s) by which the I1309V mutation augments 
binding remains controversial,9,13 its pronounced effects on the biophysical properties of 
the murine GPIbα–VWF-A1 bond made it suitable for gaining insight into the 
relationship between bond lifetime and the requirement for shear flow to initiate platelet 
attachment to VWF. It is well known that the application of a specific level of shear is 
essential to achieve optimal adhesion between GPIbα and VWF-A1 (termed the shear 
threshold effect). 20 Shear-induced forces are thought to influence the GPIbα–VWF-A1 
bond in two ways. As the applied force increases from low levels, the bond lifetime 
increases until it is of sufficient duration to promote effective interactions between 
platelets and VWF (termed a catch bond).38-40 It is only when force exceeds the critical 
value does the lifetime shorten and the bond ultimately rupture (termed a slip bond) in 
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accordance with Bell’s model.35 However, this concept has been challenged in a study 
suggesting that the shear threshold effect may be due to a transition of a slip bond from a 
low to high affinity state in response to a force-induced conformation change in the 
complex.41 Despite these conflicting views, our data suggest that the ability of the 
I1309V mutation to prolong the lifetime of the GPIbα–VWF-A1 bond beyond that of the 
native complex is essential for promoting platelet–VWF interactions at low flow states. 
Moreover, the process is reliant on the biophysical properties of the major contact 
interface. In the presence of the R1326H substitution, the I1039V mutation could no 
longer abolish the requirement for shear flow to support the tethering of murine rVWF-
A1 coated beads to mouse GPIbα, nor slow mouse platelet translocation velocities and 
augment platelet attachment to surface immobilized VWF-A1 containing the double 
mutation.  
It is important to note that the ability to prolong the lifetime of the GPIbα–VWF-
A1 bond is not unique to type 2B mutations as it has also been reported for snake venoms. 
This is best exemplified by the ability of botrocetin, a component of Bothrops jararaca 
venom, to promote platelet–VWF aggregation in plasma as well as contribute to the loss 
of VWF multimers and platelets from the blood.42 Interestingly, we have shown that the 
major effect of botrocetin is to increase the bond lifetime two-fold for both human and 
mouse complexes without affecting the on-rate.26 This did not involve allosteric changes 
in GPIbα or VWF-A1, but relied on the ability of the venom protein to form a biological 
clasp that prolonged their embrace. These results further support our current observations 
that the lifetime of the GPIbα–VWF-A1 bond contributes significantly to promoting 
effective platelet–VWF interactions at sites of arterial injury.  
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There has been much speculation on whether one or both of the identified binding 
surfaces between GPIbα and VWF-A1 could be targets for the prevention or treatment of 
thrombosis.43 Our current study helps clarify this issue. We demonstrate that a cyclic 
peptide (OS1) proven to alter the conformation of GPIbα so that is incapable of forming 
several key interactions with the major binding interface of VWF-A1 significantly 
reduced human platelet-mediated thrombus formation in laser-injured arterioles of VWF 
HA1
 mice. Thus, the development of such agents that can alter specific interactions 
between this receptor–ligand pair offers a powerful approach to reducing arterial 
thrombosis.  
 In summary, animals bearing specific mutations in a protein critical to promoting 
hemostasis and thrombosis help to establish an essential link between kinetic 
measurements of a receptor-ligand bond and their overall significance to a biologically 
relevant process.  In addition, our data shed new light on the cooperation between the two 
distinct GPIbα binding sites within VWF-A1 in generating a biophysical signature 
ideally suited for supporting platelet–VWF interactions to sites of arterial injury. Insights 
into how the interaction between a receptor–ligand pair can be altered by manipulating 
the kinetics of a receptor-ligand interaction are relevant to the development of therapies 
aimed at either disrupting or correcting disorders related to cell adhesion. 
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Figure legends 
 
Figure 1. I1309V mutation rescues the defect in platelet adhesion associated with the 
R1326H mutation. (A and B) Proposed models for the WT (A) and double mutant 
(I1306V, R1326H) (B) murine VWF-A1 domains (gray) in complex with murine GPIbα 
(cyan). The β-switch hairpin loop of GPIbαis shown in green and key side chains 
involved in forming the interface are shown in stick.  Zooms reveal details of the 
electrostatic interactions that may be altered by the mutations R1326H and I1309V, 
respectively. (C and D) Accumulation (C) and translocation velocity (wall shear rate of 
1,600 s-1) (D) of mouse platelets on surface-immobilized recombinant murine VWF-A1 
proteins. Platelet attachment and their subsequent motion were digitally recorded on an 
inverted Nikon microscope (Eclipse TE2000) with a plan 10X or 20X objective, 
respectively. The number of platelets attached per unit area and translocation velocities 
were determined by off-line analysis (Image-Pro Plus, Media Cybernetics). Data are 
representative of the mean of three separate experiments performed in triplicate (± 
standard deviation). 
 
Figure 2. Kinetics of tether bond formation and dissociation. (A) Frequency of 
transient adhesive interactions between microspheres coated with recombinant VWF-A1 
protein and surface-immobilized mouse platelets (wall shear rates 10 s-1 to 300 s-1). (B–E) 
Representative graphs depicting the distribution of pause times for more than 30 
individual transiently tethered VWF-A1 coated microspheres at the indicated wall shear 
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stresses. The dissociation rate constant (koff) is the negative slope of the linear regression 
through the experimental data. (F) Effect of force on the GPIbα–VWF-A1 tether bond as 
a function of koff. pN, piconewtons. Tethering frequency and estimation of koff values for 
VWF-A1 coated microspheres transiently interacting with surface-immobilized platelets 
were determined by recording digital images with a Nikon 10X plan or 60X DIC 
objective (oil immersion) at frame rates of 30fps or 235 fps, respectively (Speed Vision 
Technologies, San Diego, CA). Results represent the mean ± standard deviation.  
 
Figure 3. Hemostatic and thrombotic properties of plasma VWF  I1309V, R1326H. (A) 
Tail bleeding times for WT, VWF KO, VWF R1326H, and VWF I1309V, R1326H mice.  Each 
point represents one individual animal; lines show the mean of each group. (B) Thrombus 
formation in laser-injured arterioles of WT and VWF mutant mice (n = 7 mice per 
genotype; 1 arteriole per mouse). Platelet-vessel wall interactions were visualized 
through a 20X water-immersion objective (Olympus LUMPlanFl, 0.5 NA) using a Zeiss 
Axiotech Vario microscope equipped with a Yokogawa CSU-22 spinning disk confocal 
scanner, iXON EM camera, and 561 nm laser line to detect rhodamine-labeled mouse 
platelets (Revolution XD, Andor™ Technology). The extent of thrombus formation was 
assessed for 2 min post injury and the area (µm2) of coverage determined by off-line 
analysis (Image IQ, Andor™ Technology and Image-Pro Plus, Media Cybernetics).  (C 
and D) Accumulation (C) and translocation velocities (wall shear rate 1,600 s-1) (D) of 
mouse platelets on surface-immobilized WT or mutant plasma VWF at the indicated wall 
shear rates (n = 3 separate experiments). Images were obtained using a CCD camera and 
analyzed using Image-Pro Plus. Data are the mean ± standard deviation, ns = not 
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significant (P > 0.05). *P < 0.05 and **P < 0.0001 relative to control.  
 
Figure 4. Disrupting the major contact interface with the allosteric inhibitor OS1 
limits human platelet–VWF interactions. (A) Ribbon representation of the human 
GPIbα–VWF-A1–OS1 ternary complex (upper panel). The change in R-loop 
conformation imposed upon OS1 cyclic peptide (purple) binding to GPIbα is depicted in 
the panel on the right. (B and C) OS1 peptide is specific for human GPIbα. (B) 
Accumulation of mouse platelets on surface-immobilized murine rVWF-A1 protein (wall 
shear rate of 1,600 s-1) in the absence of presence of the inhibitor (n=3). Images were 
obtained with a CCD camera and analyzed using Image-Pro Plus (C) Thrombus 
formation in laser injured arterioles of WT mice animals that received an infusion of 
vehicle control or OS1 peptide  (n = 7 mice per treatment condition; 1 arteriole per 
mouse). Fluorescent imagines were obtained using a 20X water-immersion objective, a 
Yokogawa CSU-22 spinning disk confocal scanner, and a 561 nm laser line to detect 
rhodamine-labeled mouse platelets. (D) Accumulation of human platelets on surface-
immobilized human VWF-A1 protein (wall shear rate of 1,600 s-1) in the absence or 
presence of the inhibitor (n=3). Images were obtained using a CCD camera and analyzed 
using Image-Pro Plus. (E) Ristocetin-induced aggregation of human platelets in the 
presence of human plasma. Data are the mean ± standard deviation, ns = not significant 
(P > 0.05). 
 
 32
Figure 5. Hemostatic and thrombotic properties of plasma VWF  HA1.  (A) Tail 
bleeding times for WT, VWF R1326H, and VWF HA1 mice.  Each point represents one 
individual animal; lines show the mean of each group. (B) Thrombus formation in laser-
injured arterioles of WT and VWF mutant mice (n = 7 mice per genotype; 1 arteriole per 
animal). Fluorescent imagines were obtained using a 20X water-immersion objective, a 
Yokogawa CSU-22 spinning disk confocal scanner, and a 561 nm laser line to detect 
rhodamine-labeled mouse platelets. (C) Accumulation of mouse platelets on surface-
immobilized WT or mutant plasma VWF at a wall shear rate of 1,600 s-1 (n = 3). Images 
were obtained using a CCD camera and analyzed using Image-Pro Plus. (D) Human 
platelet mediated thrombus formation in laser injured arterioles of WT or VWF mutant 
animals (n = 7 mice per genotype; 1 arteriole per animal). A 488 nm laser line was used 
to detect BCECF-labeled human platelets. (E) Accumulation of human platelets on 
surface-immobilized WT or mutant plasma VWF at a wall shear rate of 1,600 s-1 (n = 3). 
(F) Representative plot depicting the extent of ristocetin-induced agglutination / 
aggregation of lyophilized human platelets in plasma from human volunteers or VWF 
mutant animals (n = 2 experiments performed in duplicate). Data are the mean ± standard 
deviation, ns = not significant (P > 0.05).  
 
Figure 6. Disrupting the major contact interface between human GPIbα and VWF 
HA1
 reduces arterial thrombus formation. (A and B) Effect of the OS1 peptide on 
human platelet accumulation on surface-immobilized plasma VWF HA1 (wall shear rate of 
1,600 s-1; n=3) (A) and ristocetin-induced human platelet aggregation in the presence of 
plasma from VWF HA1 animals (B; n=2). Images were obtained using a CCD camera and 
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analyzed using Image-Pro Plus. (C) Effect of OS1 peptide on human platelet-mediated 
thrombus formation in arterioles of VWF HA1 mice (n = 7 mice per genotype; 1 arteriole 
per animal). A 488 nm laser line was used to detect BCECF-labeled human platelets. 
Data are the mean ± standard deviation. **P < 0.001 relative to control.  
 






Table 1. Intrinsic dissociation rates constants (k0off) and reactive compliance (σ) values 
for murine GPIbα–VWF-A1 tether bond 
 
 
 
 
 
 
Values were determined by using maximal likelihood statistical estimates of Bell 
parameters.  
 
 
Mouse rVWF–A1 
 
k0off  (s-1) 
 
σ (nm) 
 
R2 
 
WT 
 
R1326H 
 
I1309V 
 
I1309V, R1326H 
3.05 ± 0.55 
  
7.80 ± 1.15 
  
0.49± 0.04 
 
4.15 ± 0.67 
0.028 ± 0.001 
 
0.039 ± 0.002 
 
0.020 ± 0.003 
 
0.028 ± 0.001 
0.97 
 
0.93 
 
0.95 
 
0.94 
